Cell surface p32, the target of LyP‐1 homing peptide, was up‐regulated in tumour endothelial cells (blood and lymphatic) and tumour cells.25 p32 has been regarded as a tumour‐specific target, and LyP‐1 had been used for targeting of drugs and nanoparticles in tumour and metastatic tumours in lymph nodes.26 The application of LyP‐1 peptides as coating surface to enhance drug delivery had been recently investigated.19 In this study, we used LyP‐1‐fMWNTs as a gene delivery system. The gene discussed is PTPN22; the disease is neoplasm.